R&D Funding & Commercialization

Investing in new designs, prototyping, and testing new materials is expensive and can strain budgets, especially for Small and Medium-sized Enterprises (SMEs).

The high cost and extended timelines for R&D, clinical trials, and regulatory approval severely limit new market entrants.

Despite its foundational role, defence spending is often perceived as a necessary cost rather than a productive investment, leading to political pressures for budget cuts during times of peace, potentially impacting long-term R&D and capabilities.

Lengthy and complex approval processes for research projects (e.g., clinical trials) delay time-to-market for innovations and can deter investment in high-risk areas.

Power outages can destroy invaluable biological samples, chemical reagents, and experimental data, leading to significant financial losses and setbacks in research progress.

Inconsistent data formats and metadata hinder the ability to reproduce experimental results, a cornerstone of scientific rigor, leading to questions about research validity and trust.

The inability to consistently reproduce experimental results undermines scientific credibility, wastes resources, and can lead to flawed policy decisions or product development, eroding public and investor trust.

Difficulty in measuring the return on investment for new, unproven ad formats or technologies, leading to hesitation in large-scale adoption.